On 1 June 2016, Auris Medical Holding AG launched a controlled equity offering by entering into a sales agreement with Cantor Fitzgerald & Co. Pursuant to the terms of the agreement, Auris Medical may offer and sell its common shares from time to time through Cantor Fitzgerald, as the company’s sales agent.
Under the agreement, Cantor Fitzgerald may sell shares by any method deemed to be an “at the market (ATM) offering”. Sales of the shares are to be made under the company’s shelf registration statement for an aggregate offering price of up to $35m.
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The shares of Auris Medical trade on the NASDAQ Global Market.
Walder Wyss advises Auris Medical on Swiss law aspects of the transaction. The team is being led by Alexander Nikitine (Partner, Capital Markets, Corporate/M&A) and further includes Sarah Schulthess (Associate, Capital Markets, Corporate/M&A), Maurus Winzap (Partner, Tax) and Fabienne Limacher (Associate, Tax). Davis Polk & Wardwell advises Auris Medical on US law aspects. Cooley (as to US law) and Homburger (as to Swiss law) act as legal advisers to Cantor Fitzgerald & Co.
